Phase 3 N=393 Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
Chronic Iron Overload
Primary: Percentage of Successfully Chelated Patients — 69; 80 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=100 Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease
Glycogen Storage Disease Type II;Pompe's Disease
Primary: PAP: Change From Baseline in Percent Predicted FVC in Upright Position at Week 49 — 2.89; 0.46 percent predicted FVC — p=0.0074
Phase 3 N=150 Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
Varicella
Primary: Varicella Zoster Virus (VZV) Antibody Response Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline — 100.0; 100.0; 95.5; 100.0…
Phase 3 N=191 A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease
Crohn's Disease
Primary: Clinical Improvement Rate (Number of Subjects Showing Clinical Improvement / Number of Subjects Evaluated × 100) After 8 Weeks of IMP Administration — 31.3; 21.0; 29.5…
Phase 3 N=1,182 Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Primary: Overall Survival, Intention-to-treat Population — 23.9; 24.3 Months — p=0.596
Phase 3 N=374 Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness
Chronic Obstructive Pulmonary Disease
Primary: Baseline Adjusted Mean Change in FEV1 AUC0-24h Post Dose — 2.5644; 2.7370 L*hour
Phase 3 N=358 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
Ulcerative Colitis
Primary: Percentage of Participants in Remission at Week 10 With Etrolizumab as Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28948 Population — 6.9…
Phase 3 N=10 Bilateral Continuous Erector Spinae Blocks for Post-Sternotomy Pain Management: A Pilot Study
Pain, Postoperative
Primary: Number of Participants Who Completed a Successful Intervention With No Major Adverse Events — 10 Participants
Phase 3 N=165 Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16…
Phase 3 N=901 Safety and Efficacy of KPI-121 in Subjects With DED
Kerato Conjunctivitis Sicca
Primary: Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) — -13.58; -8.91 score on a scale
Phase 3 N=801 Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
Glabellar Lines
Primary: Incidence of Adverse Events (AEs) — 374 Participants
Phase 3 N=33 Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
SMA
Primary: Number of Participants Who Achieve Independent Sitting for at Least 10 Seconds — 14 Participants
Phase 3 N=20 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Myasthenic Syndromes, Congenital
Primary: Subject Global Impression (SGI) Score Summary: Mann-Whitney Main Effects Test Results; SGI Score Mixed Model Analysis — -0.13; -1.75; -0.75; -1.14 Scores on a scale…
Phase 3 N=197 Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
Cholera
Primary: % of Participants With Moderate to Severe Diarrhea — 5.7; 59.1 percentage of participants
Phase 3 N=801 A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)
Acne Vulgaris
Primary: Absolute Change in Mean Lesion Counts at Week 12 — -24.6; -16.6; -16.7; -13.4 lesion counts